Corbus Pharmaceuticals Holdings Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
On March 14, 2025, Yuval Cohen, Ph.D., the Company's Chief Executive Officer and a member of the board of directors adopted a Rule 10b5-1 plan providing for the sale of up to 205,253 shares of the Company’s common stock. Pursuant to this plan, Dr. Cohen may sell shares of common stock beginning on October 24, 2025, subject to the terms of the agreement, and the plan terminates on March 15, 2026. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
Also on March 14, 2025, Sean Moran, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 94,179 shares of common stock. Pursuant to this plan, Mr. Moran may sell shares beginning on October 24, 2025, subject to the terms of the agreement, and the plan terminates on March 15, 2026. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
No other directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the first quarter of 2025.
-24-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.